Value of serum FAM19A5 and vitronectin in evaluating the degree of coronary artery disease and major adverse cardiovascular eventsin patients with coronary heart disease complicated with heart failure
10.3969/j.issn.1673-4130.2025.02.012
- VernacularTitle:血清FAM19A5、vitronectin对冠心病合并心力衰竭患者冠状动脉病变程度及主要不良心血管事件的评估价值
- Author:
Boting CHEN
1
;
Yingxue CUI
;
Xiaoyan GUO
Author Information
1. 西安市第九医院心血管病院三科(老年病科),陕西西安 710054
- Keywords:
coronary heart disease;
heart failure;
family with sequence similarity 19 member A5;
vitronectin;
degree of coronary artery disease;
major adverse cardiovascular events
- From:
International Journal of Laboratory Medicine
2025;46(2):191-195,200
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of serum family with sequence similarity 19 member A5(FAM19A5)and vitronectin in evaluating the degree of coronary artery disease and major adverse cardiovas-cular events(MACE)in patients with coronary heart disease(CHD)complicated with heart failure(HF).Methods From March 2022 to March 2023,120 patients with CHD complicated with HF in this hospital were collected as the study group,and 76 healthy individuals who underwent physical examination in the hospital were as the control group.Patients in the study group were divided into mild group(41 cases),moderate group(59 cases)and severe group(20 cases)according to Gensini score and degree of coronary artery dis-ease.Meanwhile,they were divided into MACE group(36 cases)and non-MACE group(84 cases)according to whether MACE occurred 6 months after treatment.Serum FAM19A5 and vitronectin levels were detected by enzyme-linked immunosorbent assay(ELISA),and the correlation between serum FAM19A5 and vitronec-tin levels and Gensini score in CHD patients with HF was analyzed by Pearson method.Multivariate Logistic regression was used to analyze the influencing factors of MACE in CHD patients with HF,and receiver operat-ing characteristic(ROC)curve was used to evaluate the predictive value of FAM19A5 and vitronectin for MACE in CHD patients with HF.Results The serum FAM19A5 level in the study group was significantly decreased(P＜0.05),and the serum vitronectin level was significantly increased(P＜0.05).The serum FAM19A5 level in severe group was significantly lower than that in mild and moderate groups(P＜0.05),and the serum vitronectin level was significantly higher than that in mild and moderate groups(P＜0.05).The serum FAM19A5 level in MACE group was significantly lower than that in non-MACE group(P＜0.05),and the serum vitronectin level was significantly higher than that in no-MACE group(P＜0.05).Ser-um FAM19A5 level in CHD patients with HF was negatively correlated with Gensini scores(r=-0.755,P＜0.001),and vitronectin level was positively correlated with Gensini scores(r=0.697,P＜0.001).The risk factors for MACE in CHD patients with HF were cardiac function grade Ⅲ-Ⅳ,decreased FAM19A5 lev-el,increased LDL-C,vitronectin level and Gensini scores(P＜0.05).The area under the curve(AUC)of ser-um FAM19A5,vitronectin and the combination of FAM19A5 and Vitronectin were 0.882,0.877,and 0.962,respectively,which were superior to the AUC of FAM19A5 and Vitronectin alone(Z=2.612,2.188,P=0.009,0.029).Conclusion The serum levels of FAM19A5 and vitronectin are significantly correlated with the degree of coronary artery disease in CHD patients with HF,and the combination of Fam19A5 and Vitronectin has a high predictive value for the occurrence of MACE.
